Physician profile
Roberto A Espada
NPI 1548231962
$2,314.25
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,717 · 2020: $84.58 · 2021: $131 · 2022: $58.10 · 2023: $292 · 2024: $31.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241 · Education: $82.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $240.89 |
| Education | $82.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,482.39 | 2019 | |
| Abbvie INC. | $176.61 | 2019-2023 | |
| Astellas Pharma US INC | $155.89 | 2023-2024 | Myrbetriq, Veozah |
| Davol INC. | $115.60 | 2023 | Arista Ah Flexitip |
| Lupin INC. | $108.13 | 2019-2020 | |
| Intuitive Surgical, INC. | $97.66 | 2019-2024 | |
| Myovant Sciences INC. | $39.27 | 2021 | |
| Allergan, INC. | $26.01 | 2019-2020 | |
| Scynexis, INC. | $25.63 | 2022 | |
| Hologic Sales and Service, LLC | $22.13 | 2020 | |
| Exeltis, USA INC. | $18.55 | 2019 | |
| Smith+Nephew, INC. | $16.67 | 2022 | |
| Mission Pharmacal Company | $15.44 | 2021 | |
| Evofem Biosciences, INC. | $14.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Espada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.